Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase I clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma, with the potential to bring the benefit of cell therapy to patients who lack curative options.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.

June 12, 2026

Vol.52 No.23

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.

May 15, 2026

Vol.52 No.19

By Dan G. Duda

Clinical Roundup

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first-in-the-world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment.

May 08, 2026

Vol.52 No.18

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

YOU MAY BE INTERESTED IN

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

AI in action: MANAscore tool moves closer to clinic

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login